Drug Trial Radar · NCT01206660
Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Jul 3, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
120
Actual
Start
Aug 2010
Primary completion
Dec 2010
Study completion Jan 2011
Sponsor
- Lead sponsor
- Sun Pharmaceutical Industries, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 22, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to demonstrate that desoximetasone 0.25% topical spray is effective for the treatment of patients with moderate to severe plaque psoriasis.
Conditions
- Psoriasis
Interventions
Desoximetasone Spray 0.25%Drug
Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
placeboDrug
Placebo administered to affected area twice a day for 28 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Success ITTTime frame: 28 days
- Treatment SuccessTime frame: Day 28
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Investigator Site
Hazleton, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.